These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 21725611)

  • 21. Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer.
    Owen S; Ye L; Sanders AJ; Mason MD; Jiang WG
    Anticancer Res; 2013 Jan; 33(1):199-206. PubMed ID: 23267146
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression and function of RANK in human monocyte chemotaxis.
    Mosheimer BA; Kaneider NC; Feistritzer C; Sturn DH; Wiedermann CJ
    Arthritis Rheum; 2004 Jul; 50(7):2309-16. PubMed ID: 15248232
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation.
    Wang C; Steer JH; Joyce DA; Yip KH; Zheng MH; Xu J
    J Bone Miner Res; 2003 Dec; 18(12):2159-68. PubMed ID: 14672351
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo.
    Jallal H; Valentino ML; Chen G; Boschelli F; Ali S; Rabbani SA
    Cancer Res; 2007 Feb; 67(4):1580-8. PubMed ID: 17308097
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
    Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
    Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of non-receptor and receptor tyrosine kinases (TKs) in the antitumor action of alpha-difluoromethylornithine (DFMO) in breast cancer cells.
    Xu H; Washington S; Verderame MF; Manni A
    Breast Cancer Res Treat; 2008 Nov; 112(2):255-61. PubMed ID: 18097746
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Carbonic anhydrase XII promotes invasion and migration ability of MDA-MB-231 breast cancer cells through the p38 MAPK signaling pathway.
    Hsieh MJ; Chen KS; Chiou HL; Hsieh YS
    Eur J Cell Biol; 2010 Aug; 89(8):598-606. PubMed ID: 20434230
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CD24 enhances DNA damage-induced apoptosis by modulating NF-κB signaling in CD44-expressing breast cancer cells.
    Ju JH; Jang K; Lee KM; Kim M; Kim J; Yi JY; Noh DY; Shin I
    Carcinogenesis; 2011 Oct; 32(10):1474-83. PubMed ID: 21798852
    [TBL] [Abstract][Full Text] [Related]  

  • 29. OPG/membranous--RANKL complex is internalized via the clathrin pathway before a lysosomal and a proteasomal degradation.
    Tat SK; Padrines M; Theoleyre S; Couillaud-Battaglia S; Heymann D; Redini F; Fortun Y
    Bone; 2006 Oct; 39(4):706-15. PubMed ID: 16750945
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Insulin like growth factor binding protein-7 reduces growth of human breast cancer cells and xenografted tumors.
    Amemiya Y; Yang W; Benatar T; Nofech-Mozes S; Yee A; Kahn H; Holloway C; Seth A
    Breast Cancer Res Treat; 2011 Apr; 126(2):373-84. PubMed ID: 20464481
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Src and Cas are essentially but differentially involved in angiotensin II-stimulated migration of vascular smooth muscle cells via extracellular signal-regulated kinase 1/2 and c-Jun NH2-terminal kinase activation.
    Kyaw M; Yoshizumi M; Tsuchiya K; Kagami S; Izawa Y; Fujita Y; Ali N; Kanematsu Y; Toida K; Ishimura K; Tamaki T
    Mol Pharmacol; 2004 Apr; 65(4):832-41. PubMed ID: 15044612
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Arachidonic acid induces an increase of β-1,4-galactosyltransferase I expression in MDA-MB-231 breast cancer cells.
    Villegas-Comonfort S; Serna-Marquez N; Galindo-Hernandez O; Navarro-Tito N; Salazar EP
    J Cell Biochem; 2012 Nov; 113(11):3330-41. PubMed ID: 22644815
    [TBL] [Abstract][Full Text] [Related]  

  • 33. JNK/c-Jun signaling mediates an anti-apoptotic effect of RANKL in osteoclasts.
    Ikeda F; Matsubara T; Tsurukai T; Hata K; Nishimura R; Yoneda T
    J Bone Miner Res; 2008 Jun; 23(6):907-14. PubMed ID: 18251700
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cdc42 negatively regulates intrinsic migration of highly aggressive breast cancer cells.
    Zuo Y; Wu Y; Chakraborty C
    J Cell Physiol; 2012 Apr; 227(4):1399-407. PubMed ID: 21618528
    [TBL] [Abstract][Full Text] [Related]  

  • 35. RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4-dependent pathway.
    Panizo S; Cardus A; Encinas M; Parisi E; Valcheva P; López-Ongil S; Coll B; Fernandez E; Valdivielso JM
    Circ Res; 2009 May; 104(9):1041-8. PubMed ID: 19325147
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Temporal and quantitative regulation of mitogen-activated protein kinase (MAPK) modulates cell motility and invasion.
    Krueger JS; Keshamouni VG; Atanaskova N; Reddy KB
    Oncogene; 2001 Jul; 20(31):4209-18. PubMed ID: 11464287
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells.
    Mancino AT; Klimberg VS; Yamamoto M; Manolagas SC; Abe E
    J Surg Res; 2001 Sep; 100(1):18-24. PubMed ID: 11516200
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-tumor effect in human breast cancer by TAE226, a dual inhibitor for FAK and IGF-IR in vitro and in vivo.
    Kurio N; Shimo T; Fukazawa T; Takaoka M; Okui T; Hassan NM; Honami T; Hatakeyama S; Ikeda M; Naomoto Y; Sasaki A
    Exp Cell Res; 2011 May; 317(8):1134-46. PubMed ID: 21338601
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regulation of vitamin D receptor expression via estrogen-induced activation of the ERK 1/2 signaling pathway in colon and breast cancer cells.
    Gilad LA; Bresler T; Gnainsky J; Smirnoff P; Schwartz B
    J Endocrinol; 2005 Jun; 185(3):577-92. PubMed ID: 15930183
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Carvedilol suppresses migration and invasion of malignant breast cells by inactivating Src involving cAMP/PKA and PKCδ signaling pathway.
    Dezong G; Zhongbing M; Qinye F; Zhigang Y
    J Cancer Res Ther; 2014; 10(4):998-1003. PubMed ID: 25579542
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.